Goldman reiterates bullish rating on Amgen, sees Kyprolis sales ahead of consensus

Goldman is out with an update on IMS data for some of Amgen's (AMGN) key drugs.

"Sales are tracking slightly ahead of our estimates," analyst Terence Flynn says, adding that "Kyprolis, Epogen and Prolia are particularly strong, while Enbrel and Neulasta are tracking in-line and Aranesp is slightly below."

Flynn sees Q4 Kyprolis sales coming in at $76M versus consensus of $71M.

AMGN reiterated at Buy.

Price target is $130.

From other sites
Comments (1)
  • mjgleason
    , contributor
    Comment (1) | Send Message
    Target price is $140
    1 Dec 2013, 07:31 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs